$BCRX News

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

BioCryst Pharma To Present Seven Abstracts From Hereditary Angioedema Portfolio At Annual Meeting Of EAACI 2026

BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026

BioCryst Pharmaceuticals To Present New Real-World Evidence At The International Society For Pharmacoeconomics And Outcomes Research Conference, May 17–20

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

BioCryst (BCRX) Is Down 6.7% After Q1 Loss And Navenibart Deal News Has The Bull Case Changed?

A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Q1 Results And Navenibart Licensing Deal

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings

Citizens Maintains Market Outperform on BioCryst Pharma, Raises Price Target to $28

Wedbush Maintains Outperform on BioCryst Pharma, Lowers Price Target to $21

BioCryst (BCRX) Q1 2026 Earnings Transcript

BioCryst Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary

BioCryst Pharmaceuticals Q1 Earnings Call Highlights

Needham Maintains Buy on BioCryst Pharma, Lowers Price Target to $16

BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Q1 2026 Results: Revenue Beat, EPS Miss

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2026 Earnings Call Transcript

BioCryst Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

Full Transcript: BioCryst Pharma Q1 2026 Earnings Call